While Editas Medicine Inc has underperformed by -3.20%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT fell by -88.83%, with highs and lows ranging from $11.58 to $1.24, whereas the simple moving average fell by -72.92% in the last 200 days.
On December 16, 2024, JP Morgan Downgraded Editas Medicine Inc (NASDAQ: EDIT) to Underweight. A report published by Truist on December 13, 2024, Downgraded its rating to ‘Hold’ for EDIT. Stifel also Downgraded EDIT shares as ‘Hold’, setting a target price of $3 on the company’s shares in a report dated December 13, 2024. Wells Fargo December 11, 2024d its ‘Overweight’ rating to ‘Equal Weight’ for EDIT, as published in its report on December 11, 2024. BofA Securities’s report from November 25, 2024 suggests a price prediction of $1 for EDIT shares, giving the stock a ‘Underperform’ rating. Evercore ISI also rated the stock as ‘Outperform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Editas Medicine Inc (EDIT)
Further, the quarter-over-quarter decrease in sales is -98.86%, showing a negative trend in the upcoming months.
One of the most important indicators of Editas Medicine Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -78.56% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.75, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and EDIT is recording 2.47M average volume. On a monthly basis, the volatility of the stock is set at 9.40%, whereas on a weekly basis, it is put at 8.91%, with a loss of -20.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.17, showing growth from the present price of $1.21, which can serve as yet another indication of whether EDIT is worth investing in or should be passed over.
How Do You Analyze Editas Medicine Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.93%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 67.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EDIT shares are owned by institutional investors to the tune of 67.85% at present.
